NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
Clinical Trials
44 trialsNCT05048901 2026-04-09
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT07453225 2026-03-05
Empirical Radioactive Iodine Therapy in DTC
Assiut University
Phase 1/2 Not yet recruiting
NCT04785287 2026-03-03
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT04530916 2025-11-17
WB2020
Colorado State University
Phase 1/2 Active not recruiting
NCT05385861 2025-08-15
Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET
National Health Research Institutes, Taiwan
Phase 1/2 Enrolling by invitation
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT06455358 2025-05-30
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
University Hospital, Basel, Switzerland
Phase 1/2 Recruiting
NCT03145857 2025-05-14
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
AHS Cancer Control Alberta
Phase 1/2 Recruiting
NCT06456723 2025-05-01
FETONET
Imperial College London
Phase 1/2 Completed
NCT06056362 2025-04-02
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1/2 Recruiting
NCT02348749 2025-03-19
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02736500 2025-01-13
LuX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1/2 Completed
NCT02749331 2024-12-03
RADNET
Uppsala University
Phase 1/2 Active not recruiting
NCT06038461 2024-10-01
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT04614766 2024-04-29
SPORE-3
University of Iowa
Phase 1/2 Withdrawn
NCT02244463 2024-01-12
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT06155994 2023-12-05
68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours
Medical University Innsbruck
Phase 1/2 Completed
NCT03043664 2023-06-29
PLANET
Duke University
Phase 1/2 Completed
NCT03475953 2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2 Unknown
NCT05747729 2023-02-28
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT02205515 2022-08-19
EBRT
Sunnybrook Health Sciences Centre
Phase 1/2 Completed
NCT04318561 2021-12-21
PET
Peking Union Medical College Hospital
Phase 1/2 Completed
NCT01619865 2021-07-27
GA-68
University of Iowa
Phase 1/2 Completed
NCT03189953 2021-06-16
GLP-1-AHH
Radboud University Medical Center
Phase 1/2 Completed
NCT03923257 2021-06-08
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Phase 1/2 Withdrawn
NCT03881306 2020-08-20
DEBOXA for Inoperable NET Liver Metastases
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT03278405 2020-03-18
NET-001
Sunnybrook Health Sciences Centre
Phase 1/2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT02030184 2019-10-17
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
Phase 1/2 Withdrawn
NCT00323076 2019-08-26
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
AHS Cancer Control Alberta
Phase 1/2 Terminated
NCT03629847 2018-08-14
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue
King Faisal Specialist Hospital & Research Center
Phase 1/2 Unknown
NCT03511768 2018-04-30
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
Xiangya Hospital of Central South University
Phase 1/2 Unknown
NCT02072252 2017-08-17
TODAY!
Northwestern University
Phase 1/2 Withdrawn
NCT02078843 2016-09-07
GaIN
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Terminated
NCT02055989 2014-02-05
A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT02038738 2014-01-17
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Phase 1/2 Unknown
NCT01471288 2011-11-15
Effect of Carum Carvi on Thyroid Hormones and TSH Level
Mashhad University of Medical Sciences
Phase 1/2 Unknown
NCT01442571 2011-09-28
Hyaluronic Acid Injection Post Arthroscopy - Does it Improve Immediate Function? Double Blind Controlled Prospective Study
Hadassah Medical Organization
Phase 1/2 Unknown
NCT00454103 2010-08-18
Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
University of Wuerzburg
Phase 1/2 Completed
NCT01175096 2010-08-04
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Guangdong Provincial People's Hospital
Phase 1/2 Unknown
NCT00077103 2010-06-11
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
Case Comprehensive Cancer Center
Phase 1/2 Terminated